Galmed Pharma Files 6-K with Q3 2025 Financials

TL;DR

Galmed Pharma dropped its Q3 2025 financials on 11/26/25 - check the balance sheet and income statement for the latest numbers.

AI Summary

Galmed Pharmaceuticals Ltd. filed a 6-K report on November 26, 2025, detailing financial information for the period ending September 30, 2025. The filing includes balance sheet data for common stock, additional paid-in capital, accumulated other comprehensive income, and retained earnings as of various dates in 2023, 2024, and 2025. It also provides quarterly income statement data for Q3 2025 and Q3 2024, as well as year-to-date data for 2025 and 2024.

Why It Matters

This filing provides investors with updated financial performance and position details for Galmed Pharmaceuticals, crucial for assessing the company's health and future prospects.

Risk Assessment

Risk Level: low — This is a routine financial filing (6-K) that provides updated financial statements and does not appear to contain significant new operational or strategic information.

Key Numbers

• Q3 2025 — Quarterly Financials (Updated income statement data for the third quarter of 2025 is presented.)
• 2025-09-30 — Reporting Period End Date (The financial data reported covers the period up to this date.)

Key Players & Entities

• Galmed Pharmaceuticals Ltd. (company) — Filer of the 6-K report
• 2025-09-30 (date) — End of the reporting period
• 2025-11-26 (date) — Filing date of the report

FAQ

Key Financial Figures

• $ — K, "NIS" means New Israeli Shekel, and "$," "US$" and "U.S. dollars" mean United

Filing Documents

• form6-k.htm (6-K) — 453KB
• ex99-1.htm (EX-99.1) — 79KB
• 0001493152-25-025070.txt ( ) — 2139KB
• glmd-20250930.xsd (EX-101.SCH) — 13KB
• glmd-20250930_cal.xml (EX-101.CAL) — 28KB
• glmd-20250930_def.xml (EX-101.DEF) — 52KB
• glmd-20250930_lab.xml (EX-101.LAB) — 155KB
• glmd-20250930_pre.xml (EX-101.PRE) — 112KB
• form6-k_htm.xml (XML) — 183KB

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of November 2025 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) 16 Abba Hillel Road , Ramat Gan , Israel 5250608 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F This Form 6-K contains the quarterly report of Galmed Pharmaceuticals Ltd. (the "Company"), which includes the Company's unaudited interim condensed consolidated financial statements for the three and nine months ended September 30, 2025, together with related information and certain other information. The Company is not subject to the requirements to file quarterly or certain other reports under Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended. The Company does not undertake to file or cause to be filed any such reports in the future, except to the extent required by law. On November 26, 2025, the Company issued a press release announcing the filing of its financial results for the three and nine months ended September 30, 2025, with the Securities and Exchange Commission. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. This Form 6-K is incorporated by reference into the Company's Registration Statement on Form S-8 (Registration Nos. 333-206292 , 333-227441 , 333-284163 and 333-290399 ) and the Company's Registration Statements on Form F-3 (Registration Nos. 333-272722 and 333-283241 ). FINANCIAL INFORMATION Financial GALMED PHARMACEUTICALS LTD. Interim Condensed Consolidated Balance Sheets (Unaudited) U.S. Dollars in thousands, except share data and per share data As of As of September 30, 2025 December 31, 2024 Assets Current assets Cash and cash equivalents $ 3,314 4,652 Short-term deposit 7,560 3,496 Restricted Cash 124 121 Marketable debt securities 8,177 7,183 Other receivables 549 672 Total current assets 19,724 16,124 Investment in associate at fair value 1,593 2,119 Loan to associate 267 257 Total non-current assets 1,860 2,376 Total assets $ 21,584 $ 18,500 Liabilities and stockholders' equity Current liabilities Trade payables $ 1,674 $ 1,308 Other payables 798 865 Total current liabilities 2,472 2,173 Stockholders' equity Ordinary shares par value NIS 1.80 per share; Authorized 900,000,000 as of September 30, 2025 and 50,000,000 as of December 31, 2024; Issued and outstanding: 5,479,231 shares as of September 30, 2025 and 1,664,884 shares as of December 31, 2024 2,786 742 Ordinary shares par value NIS 1.80 per share; Authorized 900,000,000 as of September 30, 2025 and 50,000,000 as of December 31, 2024; Issued and outstanding: 5,479,231 shares as of September 30, 2025 and 1,664,884 shares as of December 31, 2024 2,786 742 Additional paid-in capital 222,602 216,470 Accumulated other comprehensive loss ( 316 ) ( 416 ) Accumulated deficit ( 205,960 ) ( 200,469 ) Total stockholders' equity 19,112 16,327 Total liabilities and stockholders' equity $ 21,584 $ 18,500 The accompanying notes are an integral part of the interim condensed consolidated financial statements. GALMED PHARMACEUTICALS LTD. Interim Condensed Consolidated Statements of Operations (Unaudited) U.S. Dollars in thousands, except share data and per share data 2025 2024 2025 2024 Three months ended September 30, Nine months ended September 30, 2025 2024 2025 2024 Research and development expenses 1,086 738 2,778 1,907 General and administrative expenses 1,009 1,273 2,690 2,727 Total operating expenses 2,095 2,011 5,468 4,634 Financial income, net ( 203 ) ( 97 ) ( 503 ) ( 326 ) Impairment of Associate - - 526 - Net loss $ 1,892 $ 1,914 $ 5,491 $ 4,308 Basic and diluted net loss per share $ 0.33 $ 2.31 $ 1.47 $ 6.11 Weighted-average number of shares outstanding used in computing basic and diluted net loss per share 5,460,476 829,500 3,743,362 705,427 The accompanying notes are an integral part of the interim condensed consolidated financial statements. GALMED PHARMACEUTICALS LTD. Interim Condensed Consolidated Statements of Comprehensive Loss (Unaudited) U.S. Dollars in thousands 2025 2024 2025 2024 Three months ended September 30, Nine months ended September 30, 2025 2024 2025 2024 Net loss 1,892 $ 1,914 $ 5,491 $ 4,308 Other comprehensive loss: Net unrealized gain on available for sale securities ( 87 ) ( 93 ) ( 100 ) ( 112 ) Comprehensive loss 1,805 $ 1,821 $ 5,391 $ 4,196 The accompanying notes are an integral part of the interim condensed consolidated financial

View Full Filing

View this 6-K filing on SEC EDGAR